Description
(AWP Alliance News) - Basilea Pharmaceutica AG highlighted continued commercial momentum for Cresemba, citing moving annual total sales of USD 782 million for the 12 months to March 2026, up 27% year on year, with the brand marketed in 76 countries. The group outlined a growth runway for Cresemba in the US through Q4 2027, in Europe through H2 2028, with longer-duration growth expectations for Japan and other markets beyond 2028. Basilea also positioned Zevtera for expansion in the US following its July 2025 launch via partner Innoviva Specialty Therapeutics, supported by market exclusivity through April 2034. The pipeline focus remained on phase 3 programs for fosmanogepix in invasive candidiasis and invasive mold infections, alongside plans to start a global phase 3 program for oral ceftibuten-ledaborbactam in complicated urinary tract infections in mid-2027. Basilea reiterated its capital-light partnering model, pointing to about USD 440 million in non-dilutive R&D funding awarded to date, including about USD 165 million already received.
https://docs.publicnow.com/F11FEC5DEA6663D5556438412C6BBFF21AB96926
Disclaimer: This news brief was created using generative artificial intelligence. Basilea Pharmaceutica AG published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein.
